(NASDAQ: IRWD) Ironwood Pharmaceuticals's forecast annual revenue growth rate of 11.73% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 8.99%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.34%.
Ironwood Pharmaceuticals's revenue in 2026 is $361,514,000.On average, 6 Wall Street analysts forecast IRWD's revenue for 2026 to be $77,567,483,041, with the lowest IRWD revenue forecast at $74,207,723,425, and the highest IRWD revenue forecast at $80,114,052,432. On average, 6 Wall Street analysts forecast IRWD's revenue for 2027 to be $80,785,675,129, with the lowest IRWD revenue forecast at $75,336,971,390, and the highest IRWD revenue forecast at $84,504,291,970.
In 2028, IRWD is forecast to generate $82,761,036,001 in revenue, with the lowest revenue forecast at $76,466,219,355 and the highest revenue forecast at $88,461,598,250.